The federal government has been—and must remain—a critical partner in foundational technological innovation and research ...

From bars to cereals, the added-ingredient hype is everywhere. Three experts cut through the marketing to reveal the optimal ...

Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...

Prosecutors in Philadelphia say remains found buried in a wooded area behind an abandoned school are those of Kada Scott, a ...

Esteva, MD, chief of the Division of Hematology & Medical Oncology ... breast cancer who had not received previous systemic ...

In a Phase III trial, sacituzumab tirumotecan outperformed chemo in previously treated EGFR-mutant NSCLC patients, results presented at the ESMO Congress show.

GSK plc announced plans to invest $30 billion in U.S. research and manufacturing over the next five years and entered a $500 million collaboration with Hengrui Pharma for drug development. The company ...

Clinical trial results have shown that an injection therapy can reduce the size of head and neck cancer tumors. Experts have ...

MENLO PARK, CA, UNITED STATES, October 20, 2025 /EINPresswire.com/ -- SRI, along with research partners Foothold Labs and Triple Ring Technologies and commercial partner Beacon Dx Health, has been ...

He showed that specialized cells retain the genes to form an organism.

By combining proteasome inhibitors with Lys05, a drug that impairs autophagy, the team was able to shut down AML’s detour. In ...

Acute myeloid leukemia (AML), an aggressive and often fatal blood cancer, has long resisted a class of drugs called proteasome inhibitors, which work ...